BioCentury | Sep 3, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/31 cls Anadys (ANDS) Cowen Eric Schmidt Downgrade Neutral(from market outperform) -7% $2.25 Schmidt cited a lack of near-term milestones. In July, ANDS and...
BC Week In Review | Aug 6, 2007
Company News

Anadys, LG Life deal

ANDS restructured and announced it will return to LG rights to ANA380, a nucleotide analog viral polymerase inhibitor in Phase II testing to treat HBV. ANDS said it believes the HCV market is larger than...
BioCentury | Aug 6, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/3 cls Amgen (AMGN) Banc of America Securities William Sargent Price target Neutral -8% $50.90 Sargent raised his target to...
BioCentury | Aug 6, 2007
Finance

Ebb & Flow

With all the big names accounted for in the 2Q07 earnings season, the Street has rendered its verdict on the prospects going forward, punishing big pharma while giving big biotech at least the benefit of...
BC Extra | Aug 2, 2007
Company News

Anadys returns ANA380 rights, restructures

ANDS announced plans to restructure and discontinue development of ANA380, a nucleotide analog viral polymerase inhibitor in Phase II testing to treat HBV. The announcement follows last Friday's news that ANDS and partner Novartis (NVS;...
BioCentury | May 7, 2007
Finance

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/4 cls Aeterna Zentaris (TSX:AEZ; AEZS) Dundee David Martin Price target Market outperform 3% $3.96 Martin lowered his target to C$6.50 from C$7 after...
BioCentury | Jan 8, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/5 cls Aeterna Zentaris (TSX:AEZ; AEZS) Dundee David Martin Price target Market outperform -4% $ 3.87 Martin reduced his target to C$6 from C$9...
BC Week In Review | Aug 14, 2006
Company News

Anadys, Novartis deal

ANDS said NVS's exclusive option to license ANA380 has expired and that it will not extend the exclusivity period (see BioCentury, June 6, 2005). However, the company said it is in discussions with NVS for...
BioCentury | Jul 3, 2006
Finance

Anadys chronicles

Anadys chronicles Anadys (ANDS) fell $3.77 (56%) to $2.92 last week after it suspended dosing in a Phase Ib trial of HCV compound ANA975. That may be drastic, as ANDS had $99.8 million in cash...
BioCentury | Jun 12, 2006
Strategy

Infectious space at Novartis

Infectious space at Novartis Hepatitis Hospital-acquired infections Vaccines Other Mkt Cubicin for complicated skin and soft-tissue infections caused by Gram-positive bacteria (EU rights) [Chiron acq] TOBI tobramycin for P. aeruginosa lung infections in cystic fibrosis...
Items per page:
1 - 10 of 38